All
FDA panel backs MRI contrast agent
January 26th 2011A Food and Drug Administration (FDA) panel has voted unanimously to recommend approval of a new contrast agent for MRI scans, despite concerns that the agent might increase the risk of nephrogenic systemic fibrosis (NSF) in patients, MedPage Today reports.
Survey suggests wide EHR buy-in
January 19th 2011Eighty-one percent of U.S. hospitals and 41 percent of office-based physicians say they intend to register for federal incentive payments for adoption and “meaningful use” of certified electronic health record (EHR) technology, InformationWeek.com reports.
Forum focus: Food allergy guidelines
January 19th 2011New guidelines for the diagnosis and treatment of food allergy, released in December, will be examined by four panelists during a two-hour forum Feb. 5 at the annual meeting of the American Academy of Dermatology (AAD) in New Orleans, the academy announced.
CDC adds Veregen as therapeutic option
January 12th 2011PharmaDerm, based here, has announced that its Veregen Ointment (sinecatechins, 15 percent), a topical medication for the treatment of external genital and perianal warts, has been added as a new therapeutic option in the 2010 Centers for Disease Control and Prevention (CDC) Sexually Transmitted Diseases Treatment Guidelines, PRNewswire reports.
FDA approves Gardasil to prevent anal cancer
January 5th 2011The Food and Drug Administration (FDA) has approved Gardasil (human papillomavirus [HPV] quadrivalent vaccine, recombinant; Merck) for the prevention of anal cancer and associated precancerous lesions due to HPV types 6, 11, 16 and 18 in people ages 9 through 26 years, PRNewswire-USNewswire reports.
2011 Medicare physician fee schedule appears positive for dermatologists
January 1st 2011The 2011 Medicare physician fee schedule published Nov. 29 by the Centers for Medicare & Medicaid Services (CMS) offers valuable insight into reimbursement for 2011. The final rule adjusts work relative value units downward for many services, but dermatology emerges as one of winners, getting a 4 percent increase overall.
Long-term topical steroid use carries risk of potential complications
January 1st 2011If the cause of a patient's dermatitis can't be completely avoided, then topical steroids are a first line of treatment in efforts to alleviate the condition. If the dermatitis is weeping, oozing or crusted, the topical steroid can be deferred a few days to allow to dermatitis to dry out somewhat.
Ustekinumab demonstrates safety, efficacy in psoriasis treatment trials
January 1st 2011New analyses from premarketing clinical trials show that ustekinumab (Stelara, Centocor Ortho Biotech) for moderate-to-severe chronic plaque psoriasis offers sustained efficacy and has a favorable safety and tolerability profile out to three years.
Teledermatology initiative allows wider access to care
January 1st 2011Although use of teledermatology is growing, such programs face obstacles, including a lack of federal reimbursement, experts say. Still, they agree that the ability to see faraway patients' problems can be a valuable adjunct to standard clinical care.
Cosmeceuticals added to skincare regimens may delay invasive treatments
January 1st 2011Somewhere between soap and water, fillers and facial peels, are skincare regimens that can help to maintain healthy, youthful skin. Most cosmeceuticals aren't required to have approval from the Food and Drug Administration, so they often lack complete studies to support their effectiveness. But they can still play a role in giving skin a younger, fresher appearance.
New low-power lasers for hair removal rank high on patient satisfaction
January 1st 2011New low-power lasers for hair removal can deliver advances in efficacy, safety and patient comfort, according to recent studies. The LightSheer Duet diode laser (Lumenis) delivers high speed and vacuum technology with its low-power HS handpiece, offering a 22 mm by 35 mm spot size.
Oxybenzone reaction in sunscreen could be cause of allergy complaints
January 1st 2011Sunscreen allergy may be on the rise in your practice because of the increased use of oxybenzone. Oxybenzone absorbs in the UVA range and is also used to photostabilize avobenzone. Its use has been increasing since the concept of photostabilization entered the sunscreen market.
Dermatology training programs court residents, seek alternative funding
January 1st 2011Dermatology training programs continue to confront the practitioner shortage by courting residents likely to work in underserved markets, encouraging altruism and, increasingly, using nongovernmental money to fund residency slots, experts say.
Moral beliefs guide doctors' decisions during ethical dilemmas
January 1st 2011Recently, a 78-year-old woman for whom I had cared in the past returned with a complaint of numerous growths on her neck. I informed the patient that I would be happy to remove her skin tags, but there was no medical indication to do so. The treatment would not be an insurance-covered service. She was not at all happy about this response.
Adjust investment practices to reduce risks, withstand struggling economy
January 1st 2011If you're like most Americans, you feel less secure about the U.S. economy. Certainly, this is justified. It's crucial that savvy investors - including physicians - learn from the past two years and adjust their investment behavior accordingly.
Topical imiquimod for lentigo maligna requires careful follow-up
January 1st 2011In a recent study, topical imiquimod 5 percent (Aldara, Graceway) showed efficacy against lentigo maligna (LM) (the in situ form of lentigo maligna melanoma), but the study's lead author cautions that long-term follow-up is crucial for patients treated with it.